Pamidronate treatment in bone fibrous dysplasia in children and adolescents with McCune-Albright syndrome.
Thirteen patients with McCune-Albright syndrome (MAS) and bone fibrous dysplasia (BFD) have been treated for 2-6 years with pamidronate, an aminobisphosphonate which inhibits osteoclastic function. MAS is a rare genetic condition caused by constitutive activating mutations of the Gs protein and manifests with skin dysplasia, bone fibrous dysplasia, and multiple endocrinopathies. Raised serum alkaline phosphatase and urinary hydroxyproline have been reported in these patients, indicating bone metabolic hyperactivity. Encouraging therapeutic results have been achieved with pamidronate, mainly in adults. In our study, treatment reduced bone pain, fracture rate and metabolic indices of bone turnover, in particular significantly decreased bone alkaline phosphatase and cross-links (Wilcoxon test; p <0.06), and increased bone mineral density (DEXA). Signs of healing, such as thickening of the cortical bone, were found in some patients. Three patterns of MRI were found: homogeneous hypointense fibrous tissue, 'dotted' hypointense fibrous tissue, and hyperintense cystic images. Pamidronate treatment can be considered a favorable therapeutic option for patients with MAS.
Matarazzo
P
P
Department of Pediatric Endocrinology, Regina Margherita Children's Hospital, Turin, Italy. matarpat@libero.it
Lala
R
R
Masi
G
G
Andreo
M
M
Altare
F
F
de Sanctis
C
C
D000293:Adolescent; D000328:Adult; D000469:Alkaline Phosphatase / Q000378:metabolism; D001827:Body Height / Q000187:drug effects; D015519:Bone Density / Q000187:drug effects; D001842:Bone and Bones / Q000000981:diagnostic imaging / Q000187:drug effects / Q000378:metabolism; D002648:Child; D004164:Diphosphonates / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005357:Fibrous Dysplasia of Bone / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D005359:Fibrous Dysplasia, Polyostotic / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D050723:Fractures, Bone / Q000453:epidemiology / Q000517:prevention & control; D006801:Humans; D008297:Male; D015675:Osteocalcin / Q000378:metabolism; D010146:Pain / Q000209:etiology; D000077268:Pamidronate; D011859:Radiography
D004164:Diphosphonates; D015675:Osteocalcin; D000469:Alkaline Phosphatase; D000077268:Pamidronate